Annual EBIT
-$222.54 M
+$450.62 M+66.94%
31 December 2023
Summary:
CRISPR Therapeutics AG annual earnings before interest & taxes is currently -$222.54 million, with the most recent change of +$450.62 million (+66.94%) on 31 December 2023. During the last 3 years, it has risen by +$131.90 million (+37.21%). CRSP annual EBIT is now -159.58% below its all-time high of $391.48 million.CRSP EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$110.13 M
+$41.13 M+27.19%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly earnings before interest & taxes is currently -$110.13 million, with the most recent change of +$41.13 million (+27.19%) on 30 September 2024. Over the past year, it has increased by +$22.28 million (+16.83%). CRSP quarterly EBIT is now -114.44% below its all-time high of $762.62 million, reached on 30 June 2021.CRSP Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$332.39 M
+$22.28 M+6.28%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM earnings before interest & taxes is currently -$332.39 million, with the most recent change of +$22.28 million (+6.28%) on 30 September 2024. Over the past year, it has increased by +$91.27 million (+21.54%). CRSP TTM EBIT is now -174.21% below its all-time high of $447.92 million, reached on 30 June 2021.CRSP TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +66.9% | +16.8% | +21.5% |
| 3 y3 years | +37.2% | +14.5% | -180.8% |
| 5 y5 years | -40.0% | -179.1% | -3409.6% |
CRSP EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -159.6% | +66.9% | -258.3% | +39.9% | -180.8% | +51.6% |
| 5 y | 5 years | -159.6% | +66.9% | -114.4% | +39.9% | -174.2% | +51.6% |
| alltime | all time | -159.6% | +66.9% | -114.4% | +39.9% | -174.2% | +51.6% |
CRISPR Therapeutics AG EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$110.13 M(-27.2%) | -$332.39 M(-6.3%) |
| June 2024 | - | -$151.26 M(+7.6%) | -$354.68 M(+18.8%) |
| Mar 2024 | - | -$140.59 M(-302.0%) | -$298.64 M(+34.2%) |
| Dec 2023 | -$222.54 M(-66.9%) | $69.58 M(-152.6%) | -$222.54 M(-47.5%) |
| Sept 2023 | - | -$132.41 M(+39.1%) | -$423.66 M(-10.6%) |
| June 2023 | - | -$95.22 M(+47.7%) | -$473.64 M(-15.7%) |
| Mar 2023 | - | -$64.49 M(-51.0%) | -$561.68 M(-16.6%) |
| Dec 2022 | -$673.16 M(-280.2%) | -$131.54 M(-27.9%) | -$673.16 M(-2.1%) |
| Sept 2022 | - | -$182.39 M(-0.5%) | -$687.32 M(+8.4%) |
| June 2022 | - | -$183.26 M(+4.1%) | -$633.78 M(-303.1%) |
| Mar 2022 | - | -$175.97 M(+20.8%) | $312.10 M(-16.4%) |
| Dec 2021 | $373.53 M(-205.4%) | -$145.70 M(+13.1%) | $373.53 M(-9.2%) |
| Sept 2021 | - | -$128.85 M(-116.9%) | $411.46 M(-8.1%) |
| June 2021 | - | $762.62 M(-765.8%) | $447.92 M(-213.3%) |
| Mar 2021 | - | -$114.54 M(+6.3%) | -$395.39 M(+11.6%) |
| Dec 2020 | -$354.44 M(-858.3%) | -$107.76 M(+16.6%) | -$354.44 M(+50.4%) |
| Sept 2020 | - | -$92.40 M(+14.5%) | -$235.69 M(+5608.2%) |
| June 2020 | - | -$80.69 M(+9.7%) | -$4.13 M(-119.1%) |
| Mar 2020 | - | -$73.59 M(-770.0%) | $21.58 M(-53.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $46.74 M(-129.4%) | $10.98 M(-92.1%) | $46.74 M(-593.5%) |
| Sept 2019 | - | $139.16 M(-353.1%) | -$9.47 M(-95.2%) |
| June 2019 | - | -$54.98 M(+13.5%) | -$198.07 M(+9.8%) |
| Mar 2019 | - | -$48.42 M(+7.1%) | -$180.37 M(+13.5%) |
| Dec 2018 | -$158.94 M(+145.9%) | -$45.23 M(-8.5%) | -$158.94 M(+41.0%) |
| Sept 2018 | - | -$49.43 M(+32.6%) | -$112.74 M(+29.8%) |
| June 2018 | - | -$37.29 M(+38.1%) | -$86.88 M(+22.5%) |
| Mar 2018 | - | -$27.00 M(-2877.5%) | -$70.90 M(+9.7%) |
| Dec 2017 | -$64.65 M(+340.7%) | $972.00 K(-104.1%) | -$64.65 M(+34.3%) |
| Sept 2017 | - | -$23.57 M(+10.6%) | -$48.12 M(+22.6%) |
| June 2017 | - | -$21.31 M(+2.7%) | -$39.24 M(+11.8%) |
| Mar 2017 | - | -$20.74 M(-218.6%) | -$35.10 M(+139.3%) |
| Dec 2016 | -$14.67 M(-43.0%) | $17.50 M(-219.1%) | -$14.67 M(-66.9%) |
| Sept 2016 | - | -$14.69 M(-14.4%) | -$44.28 M(+23.7%) |
| June 2016 | - | -$17.16 M(+5331.6%) | -$35.79 M(+92.2%) |
| Mar 2016 | - | -$316.00 K(-97.4%) | -$18.63 M(+1.7%) |
| Dec 2015 | -$25.71 M(+274.7%) | -$12.12 M(+95.7%) | -$18.31 M(+195.7%) |
| Sept 2015 | - | -$6.19 M | -$6.19 M |
| Dec 2014 | -$6.86 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual earnings before interest & taxes?
- What is the all time high annual EBIT for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual EBIT year-on-year change?
- What is CRISPR Therapeutics AG quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly EBIT year-on-year change?
- What is CRISPR Therapeutics AG TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM EBIT year-on-year change?
What is CRISPR Therapeutics AG annual earnings before interest & taxes?
The current annual EBIT of CRSP is -$222.54 M
What is the all time high annual EBIT for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual earnings before interest & taxes is $391.48 M
What is CRISPR Therapeutics AG annual EBIT year-on-year change?
Over the past year, CRSP annual earnings before interest & taxes has changed by +$450.62 M (+66.94%)
What is CRISPR Therapeutics AG quarterly earnings before interest & taxes?
The current quarterly EBIT of CRSP is -$110.13 M
What is the all time high quarterly EBIT for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly earnings before interest & taxes is $762.62 M
What is CRISPR Therapeutics AG quarterly EBIT year-on-year change?
Over the past year, CRSP quarterly earnings before interest & taxes has changed by +$22.28 M (+16.83%)
What is CRISPR Therapeutics AG TTM earnings before interest & taxes?
The current TTM EBIT of CRSP is -$332.39 M
What is the all time high TTM EBIT for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM earnings before interest & taxes is $447.92 M
What is CRISPR Therapeutics AG TTM EBIT year-on-year change?
Over the past year, CRSP TTM earnings before interest & taxes has changed by +$91.27 M (+21.54%)